Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics | Moffitt
Bromodomain inhibitors in clinical trials | Download Table
Bromodomain Inhibitor Design For Epigenetic Cancer Therapies and Chemical Probes | Pomerantz Laboratory
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML | Oncogene
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer - ScienceDirect
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Clinical trials of bromodomain and extra-terminal inhibitors. | Download Table
Frontiers | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases | Pharmacology
Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing) DOI:10.1039/C8MD00198G
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology
Next-generation epigenetic inhibitors
Ongoing clinical trials evaluating BET inhibitors in hematological cancers. | Download Scientific Diagram
Clinical trials of bromodomain and extra-terminal inhibitors. | Download Table
JQ1 - Wikipedia
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer: Trends in Pharmacological Sciences
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases | RMD Open
Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma - ScienceDirect
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma | EMBO Molecular Medicine
BRD4: An emerging prospective therapeutic target in glioma: Molecular Therapy - Oncolytics
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency - ScienceDirect
A chemical toolbox for the study of bromodomains and epigenetic signaling | Nature Communications
Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects
